secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-01-31T23:59:59+00:00
Accession:  0001437749-25-002329
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports no difference between neflamapimod and placebo in DLB trial; OLE data expected Q1 2025
--------------------------------------------------------------------------------

- No discernible differences between neflamapimod 40mg TID and placebo during 16-week double-blind phase of RewinD-LB trial.
- Measured trough plasma concentrations similar to 40mg BID in prior Alzheimer's study, lower than targeted.
- Retrospective analysis suggests lower bioavailability related to age of drug batch used in double-blind phase.
- PK data from food-effect study and within-subject comparison (13 participants) indicate newer capsules achieved target concentrations.
- Topline data from first 16 weeks of open-label extension (OLE) phase expected in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925002329/0001437749-25-002329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925002329/crvo20250130_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-002329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer